**Attachment E**

**Understanding Marijuana Terminology**

**THC** - is the main psychoactive substance found in marijuana
AKA: delta-9-tetrahydrocannabinol ($\Delta^9$-THC), dronabinol

**11-Hydroxy-THC** - is the main psychoactive metabolite of THC formed in the body after marijuana consumption
AKA: Hydroxy THC, 11-Hydroxy-Δ9-tetrahydrocannabinol (11-Hydroxy-$\Delta^9$-THC), 11-OH-THC

**11-nor-9-Carboxy-THC** - is the main secondary metabolite of THC which is formed in the body after marijuana is consumed. It is NOT active.
AKA: THC-COOH (most often seen this way), Carboxy THC, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (11-nor-9-carboxy-$\Delta^9$-THC), 11-COOH-THC

**Psychoactive or Active** – causes euphoric and impairing effects (THC and 11-OH-THC)

**Not active or inactive** – does NOT cause euphoric or impairing effects (THC-COOH)

**Parent compound or parent drug** – the drug in the original form that it is ingested (THC)

**Metabolite** – a chemical created in the body as part of the process of breaking down the parent compound (11-OH-THC and THC-COOH)

**Chronic vs. Occasional** – Terms denoting frequency of use
- **Chronic** – Continuing for a long time or recurring frequently
- **Occasional** – Happening infrequently and irregularly

**Recreational vs. Medical** – Term denoting reason for use
- **Recreational** - Taken for pleasure rather than for medical reasons
- **Medical** - Relating to the science or practice of medicine

**Tolerance** - The capacity of the body to endure or become less responsive to a substance

**Compensation** - Behavior that develops either consciously or unconsciously to offset a deficiency

**Plasma vs. Whole Blood**
- **Plasma** - The colorless fluid part of blood, lymph, or milk, in which corpuscles or fat globules are suspended.
- **Whole Blood** - Blood drawn directly from the body from which none of the components, such as plasma or platelets, has been removed

**Limit of Detection (LOD)** - Lowest quantity of a drug that can be distinguished from the absence of that drug

**Limit of Quantitation (LOQ)** - Lowest amount of a drug in a sample that can be quantitatively determined

THC Research Summary
Number in ( ) correspond to the THC References 2013 document

- **Culpability** (11,12, 18)
  - Validated methods used to determine culpability
    - Crash risk correlated to THC level in blood
    - 5ng/mL THC in blood = 6.6 times more likely to be responsible for crash
  - No correlation between impairment and THC COOH in blood or urine
- **Psychomotor** skill and other types of impairment (11, 15, 16, 17)
  - Highly automated behaviors are affected most. Critical tracking (6) divided attention tasks and complex tasks are also impaired. Driving is a very complex task.
  - Lane deviation and short term / working memory for complex tasks
- A person cannot fully **compensate** for the impairment from THC even with frequent use (15, 16, 17)
  - By overcompensating for self preserved impairment someone could overcome some of the impairing effects but: only for short periods of time, only for simple tasks, not enough to totally counteract the impairment, greater demand or unexpected situations - it does not help
  - Impairment is seen in both chronic and occasional users (8)
- THC levels in whole blood are scientifically supported for DUID per se for THC
  - 2 – 5 ng/mL THC in whole blood (4, 6, 8, 11, 12, 17, 18)
  - **Impairment is dose dependent and supported by signs of impairment**
  - The level takes **frequent (chronic) use** into consideration
- **Residual levels** are1-3ng/mL THC in blood seen in chronic users (4, 10, 15, 16, 17)
    - Chronic use: Daily or near daily use often with multiple times used per day
- BMI does not effect elimination (4)
- The blood is almost never drawn onsite the delay can cause false negatives (missed window of opportunity) (8)
- The blood being tested is not randomly collected but instead collected from people which were suspected of being under the influence
  - SFSTs article 2004 – Standard Field Sobriety Tests are a moderate indicator of THC impairment. Better if you include Head Movements and Jerks (HMJ). (2)
- **Rout of administration**
  - **Oral** (10, 11, 13)
    - Peak THC levels in the blood are always lower than the same dose taken by smoking
    - For a single dose the peak is around 2-3 hours after it is taken
    - Peak can be as high as 8ng/mL whole blood
    - Oral doses can cause impairment but it is normally only seen for 1-2 hours
    - Blood THC levels after single OR multiple doses drops below 5ng/mL blood in 4-6 hours after dosing is stopped
    - In conclusion, taking THC orally is much like taking other impairing pain killers. Driving will be impaired for a short time but if they wait 4-6 hours from last dose they are ok to drive.
  - **Smoked** (1, 3, 6, 9, 15)
    - Peak THC levels in blood seen while smoking
    - Peak levels in blood can be in the 100s of ng/mL
    - Impairment highest in first hour after use (6)
    - THC levels generally drop below 5ng/mL is 3 hrs or less
- Should be noted that alcohol plus THC have additive effects on driving (8, 11, 19)

**THC References 2013:**


1. Implications of plasma Δ9 – tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers, E. Karschner, et al., *Journal of Analytical Toxicology*, 33, 2009

2. The relationship between performance on the standardized field sobriety tests, driving performance and the level of delta 9-tetrahydrocannabinol (THC) in blood, K. Papafotiou, J.D Carter, C. Stough, *Forensic Science International*. 155, 172-178, 2005

3. Acute marijuana effects on human risk taking, S. Lane, et al., *Neuropsychopharmacology*, 30, 800-809, 2005

4. Do Δ9 – tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?, E. Karschner, et al., *Addiction*. 104, 2041-2048, 2009

5. Cognitive measures in long-term cannabis users, P. Harrison MD, et al., *J Clin Pharmacol*. 42, 41S-47S, 2002

6. Cognition and motor control as a function of Δ9 – tetrahydrocannabinol in serum and oral fluid: limits of impairment, J. Ramaekers, et al., *Drug Alcohol Depend*. 85, 114-122, 2006

7. Human cannabinoid pharmacokinetics, M. Huestis, *Chemistry & Biodiversity*, 4, 1771-1804, 2007

8. Developing science-based per se limits for driving under the influence of cannabis (DUIC): Findings and recommendations by an expert panel, F. Grotenhermen, et al., September 2005

9. Estimating the time of last cannabis use from plasma Δ9 – tetrahydrocannabinol and 11-nor-9-carboxy- Δ9 – tetrahydrocannabinol concentrations, M. Huestis, A. Barnes, M. Smith, *Clinical Chemistry*. 51:12, 2289-2295, 2005

10. Δ9 – tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC, E. Schwilke, et al., *Clinical Chemistry*. 55:12, 2180-2189, 2009

11. Dose related risk of motor vehicle crashes after cannabis use: an update, Drugs, Driving and Traffic Safety, J. Verster, S. Pandi-Perumal, J. Ramaekers and J. de Gier Editors, 2009

12. Driving under the influence of cannabis: a 10-year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood, A. Jones, et al., *Addiction*, 103, 452 – 461, 2008

13. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations, M. Huestis, *The Drug Monit*, 28, 4, 2006

14. The incidence of drugs in drivers killed in Australian road traffic crashes, O. Drummer, et al., *Forensic Science International* 134, 154 – 162, 2003

15. Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence, W. Bosker, et al., *PLOS one* 8(1): e53127, 2013

16. Reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in chronic daily cannabis smokers, J. Hirvonen, et al., *Molecular Psychiatry*, 17, 642-649, 2013

17. Impact of Prolonged Cannabinoid Excretion in Chronic Daily Cannabis Smokers' Blood on Per Se Drugged Driving Laws, M. Bergamaschi, et al., *Clinical Chemistry*, 59:3 519-526, 201

18. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis, M. Asbridge, et al., *BMJ*, 344 e536 1-9, 2012

19. Impairment due to cannabis and ethanol: clinical signs and additive effects, J. Bramness, et. al., *Addiction*, 106, 1080-1087, 2010